Kashani Elham, Vassella Erik
Institute of Pathology, University of Bern, 3008 Bern, Switzerland.
Graduate School for Cellular and Biomedical Sciences, University of Bern, 3012 Bern, Switzerland.
Cancers (Basel). 2022 Oct 25;14(21):5227. doi: 10.3390/cancers14215227.
Serine/Threonine protein phosphatase 2A (PP2A) is a heterotrimeric (or occasionally, heterodimeric) phosphatase with pleiotropic functions and ubiquitous expression. Despite the fact that they all contribute to protein dephosphorylation, multiple PP2A complexes exist which differ considerably by their subcellular localization and their substrate specificity, suggesting diverse PP2A functions. PP2A complex formation is tightly regulated by means of gene expression regulation by transcription factors, microRNAs, and post-translational modifications. Furthermore, a constant competition between PP2A regulatory subunits is taking place dynamically and depending on the spatiotemporal circumstance; many of the integral subunits can outcompete the rest, subjecting them to proteolysis. PP2A modulation is especially important in the context of brain tumors due to its ability to modulate distinct glioma-promoting signal transduction pathways, such as PI3K/Akt, Wnt, Ras, NF-κb, etc. Furthermore, PP2A is also implicated in DNA repair and survival pathways that are activated upon treatment of glioma cells with chemo-radiation. Depending on the cancer cell type, preclinical studies have shown some promise in utilising PP2A activator or PP2A inhibitors to overcome therapy resistance. This review has a special focus on "glioblastoma, IDH wild-type" (GBM) tumors, for which the therapy options have limited efficacy, and tumor relapse is inevitable.
丝氨酸/苏氨酸蛋白磷酸酶2A(PP2A)是一种具有多效功能且广泛表达的异源三聚体(或偶尔为异源二聚体)磷酸酶。尽管它们都有助于蛋白质去磷酸化,但存在多种PP2A复合物,它们在亚细胞定位和底物特异性方面有很大差异,这表明PP2A具有多种功能。PP2A复合物的形成通过转录因子、微小RNA的基因表达调控以及翻译后修饰受到严格调控。此外,PP2A调节亚基之间不断进行动态竞争,这取决于时空环境;许多完整亚基可以胜过其他亚基,使其遭受蛋白水解。由于PP2A能够调节不同的促进胶质瘤的信号转导途径,如PI3K/Akt、Wnt、Ras、NF-κB等,因此PP2A的调节在脑肿瘤的背景下尤为重要。此外,PP2A还参与了胶质瘤细胞经化学放疗后激活的DNA修复和生存途径。根据癌细胞类型,临床前研究表明,使用PP2A激活剂或PP2A抑制剂克服治疗耐药性有一定前景。本综述特别关注“胶质母细胞瘤,异柠檬酸脱氢酶野生型”(GBM)肿瘤,其治疗选择疗效有限,肿瘤复发不可避免。